ClinicalTrials.gg
Not yet recruitingNCT07896590Updated Oct 27, 2026

Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma

A Phase 3 interventional study of Orelabrutinib and ICP-248 in Relapsed/Refractory Marginal Zone Lymphoma (MZL), sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Not yet recruiting at 46 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 3, Interventional, and Treatment

Updated Oct 27, 2026Newly registeredGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
292
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the efficacy of olubrutinib combined with ICP-248 compared with the olubrutinib in the treatment of r/r MZL

Read the detailed description

This is an open label, randomized, multicenter phase 3 study for adult participants with relapsed/refractory marginal zone lymphoma (R/R MZL). The main goals are to compare complete response rate (CRR) and progression free survival (PFS) between the two treatment groups assessed by an Independent Review Committee (IRC).

02

Conditions studied

  • Relapsed/Refractory Marginal Zone Lymphoma (MZL)
03

In context

Lymphoma, B-Cell, Marginal Zone

875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.

This study's planned enrollment of 292 is above the median of 40 across 681 interventional studies indexed under Lymphoma, B-Cell, Marginal Zone.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years, male or female.
  2. Histopathologically confirmed marginal zone lymphoma (including splenic, nodal, extranodal MZL subtypes).
  3. Has received at least one containing anti CD20 monoclonal antibody.
  4. Disease is .
  5. Has per 2014 Lugano classification.
  6. Meets required laboratory thresholds for hematological, liver, and renal function
  7. Females must have negative serum pregnancy test. Participants must use effective during the study.
  8. Able to comply with study procedures and assessments.
  9. Voluntarily provides written .

Exclusion criteria

Exclusion Criteria:

  1. Confirmed transformation into an aggressive lymphoma.
  2. Received anti cancer therapies within 2 weeks before first product dose.
  3. Chronic for anti cancer purpose during screening.
  4. Any investigational agent within 4 weeks before study treatment; concurrent participation in other investigational therapeutic trials.
  5. Prior disease to BTK inhibitor or BCL 2 inhibitor treatment.
  6. Prior hematopoietic stem cell transplantation or CAR T therapy.
  7. central nervous system / meningeal lymphoma involvement.
  8. Second primary within 2 years before screening.
  9. Uncontrolled cardiovascular disease.
  10. Thromboembolic events within 6 months prior to first dose.
  11. Grade 3 4 active bleeding within 2 months before screening or significant bleeding diathesis.
  12. Clinically significant gastrointestinal malabsorption, major gastrointestinal resection.
  13. Major surgery or severe trauma before first dose or planned selective surgery during study.
  14. Active infection requiring intravenous anti infective therapy; positive antibody; active /.
  15. Severe interstitial lung disease, pneumoconiosis, radiation or drug induced pneumonitis.
  16. Active disease requiring systemic therapy.
  17. Psychiatric/cognitive disorders.
  18. Substance abuse.
  19. Use of strong /P gp inhibitors / inducers within 5 drug half lives before dosing or planned concomitant intake of strong modulating agents/food during study.
  20. Received live / within 4 weeks prior to first study drug dose.
  21. Known severe /anaphylaxis to investigational products, drug class agents or tablet .
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
292 participants (estimated)

Study arms

  • Experimental
    Orelabrutinib + ICP 248

    Drug: Orelabrutinib · Drug: ICP-248

  • Active comparator
    Orelabrutinib

    Drug: Orelabrutinib

Interventions

  • Participants receive orelabrutinib 150 mg oral once daily continuous dosing; each cycle is 28 days.

  • Eligible patients will receive ICP-248 orally as per the protocol

06

What researchers measure

Primary outcomes

  1. Complete Response Rate (CRR) assessed by Independent Review Committee (IRC)

    Time frame: Approximately 3 years.

  2. Progression Free Survival (PFS) assessed by Independent Review Committee (IRC)

    Time frame: Approximately 5 years.

Secondary outcomes

  1. Objective Response Rate (ORR) and Overall Survival (OS)

    Time frame: Approximately 5 years.

  2. Duration of response (DoR), time to response (TTR)

    Time frame: Approximately 5 years.

  3. Safety endpoints include adverse events (AEs)

    Time frame: Approximately 5 years.

07

Study locations

46 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Oct 27, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2028
CompletionEst.
Jan 2032
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07896590
Responsible party
Sponsor
First posted
Oct 27, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Jan 2032 (estimated)
Last update
Oct 27, 2026

Study contacts

Jingnan Yang
Contact
CO-Clinicaltrial@innocarepharma.com
(+86)-01066609990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesutoclax

Start the discussion